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Abstract: Great progress has been made regarding the capabilities to modify somatic cell fate ever
since the technology for generation of induced pluripotent stem cells (iPSCs) was discovered in
2006. Later, induced neural progenitor cells (iNPCs) were generated from mouse and human cells,
bypassing some of the concerns and risks of using iPSCs in neuroscience applications. To overcome
the limitation of viral vector induced reprogramming, bioactive small molecules (SM) have been
explored to enhance the efficiency of reprogramming or even replace transcription factors (TFs),
making the reprogrammed cells more amenable to clinical application. The chemical induced
reprogramming process is a simple process from a technical perspective, but the choice of SM at each
step is vital during the procedure. The mechanisms underlying cell transdifferentiation are still poorly
understood, although, several experimental data and insights have indicated the rationale of cell
reprogramming. The process begins with the forced expression of specific TFs or activation/inhibition
of cell signaling pathways by bioactive chemicals in defined culture condition, which initiates the
further reactivation of endogenous gene program and an optimal stoichiometric expression of the
endogenous pluri- or multi-potency genes, and finally leads to the birth of reprogrammed cells such
as iPSCs and iNPCs. In this review, we first outline the rationale and discuss the methodology of
iPSCs and iNPCs in a stepwise manner; and then we also discuss the chemical-based reprogramming
of iPSCs and iNPCs.
Keywords: reprogramming; dedifferentiation; transdifferentiation; induced pluripotent stem cell;
induced neural progenitor cell
1. Introduction
During the past decade, pluripotency has been demonstrated to restore from adult somatic
cells through ectopically co-expressing defined transcription factors (TFs) that normally maintain
pluripotency in stem cells. This is known as cellular reprogramming [1–3]. This technology has put
the field back to the limelight and formed the “Holy Grail” of regenerative medicine. On the one
hand, this discovery brought forth a paradigm shift in our understanding that the fate of somatic
cells is switchable when providing specific reprogramming factors and appropriate environmental
stimuli; on the other hand, it paved the way for modeling human diseases by circumventing the
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critical ethical concerns and immune rejections related to application of embryonic stem cells (ESCs)
and potentially substituted ESCs for diverse clinical applications [4]. Since the pioneering study
of Takahashi and Yamanaka [1], substantial progress has been made to improve both the efficiency
and safety of the iPSC reprogramming. Patient- and disease-specific induced pluripotent stem cells
(iPSCs) have been established via viral- or nanocarrier-based method for a number of diseases, such
as multiple sclerosis [5], Alzheimer’s disease [6], amyotrophic lateral sclerosis [7], spinal muscular
atrophy [8], as well as Down syndrome, Parkinson disease, Huntington’s disease and Duchenne and
Becker muscular dystrophy [9]. However, the production of customized iPSCs is still a technical
challenge, e.g., the rationale of epigenetic reprogramming and the mechanism of its low induction
efficiency must be well documented before it becomes a routine technique.
Moreover, for further clinical applications, iPSCs need to be efficiently differentiated into the
desired cell type because pluripotent stem cells, including iPSCs and ESCs, harbor the potential
risk of teratoma formation in vivo (Table 1) [10,11]. However, the generation of sufficient amounts
of differentiated cells from iPSCs for further basic and clinical applications is complicated and
time-consuming. To overcome these obstacles, recent studies have prompted investigation into
the possibility of reprogramming somatic cells to become target cell type by direct lineage conversion,
bypassing the pluripotent state.
A number of publications have reported reprogramming of mouse and human fibroblasts
into induced neural progenitor cells (iNPCs) through viral- or chemical-induced method [12,13].
The iNPCs are capable of self-renewing and differentiating into neurons and glial, holding great
promise for both biomedical research and potential cell therapy. This lineage-restricted stem cell
reprogramming complements the iPSC technology and circumvents the difficulty of differentiating
neural cells from iPSCs. It also decreases the risk of immature tumorigenesis after the transplantation
of iPSC progeny or their derivative multipotent stem cells due to potential iPSC contamination or
incomplete differentiation [10,11].
Since iPSCs were generated in 2006 [1], this technology has been extensively studied from multiple
perspectives, making it possible to deduce the rationale of cell fate conversion from iPSC generation
although the mechanisms have not been fully understood. In this comprehensive review, we aim to
outline the rationale and systematically summarize the methodology of cellular reprogramming in
induction of iPSCs and iNPCs from somatic cells, as well as the limitations and pitfalls. In the last
section, we also discuss the chemical-based reprogramming of iPSCs and iNPCs. Finally, we briefly
discuss future perspectives on cellular transformation for clinical application.
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Table 1. Summary of viral and chemical reprogramming of induced pluripotent stem cell (iPSC) and induced neural precursor cell (iNPC).
Items Method Donor Cells Duration Characteristics of iPSCs/iNPCs
iPSC Studies
Takahashi, et al. [1] Retrovirus Mouse embryonic (MEF) andadult fibroblast 16 days Could differentiate into all three germ layers in vitro
Takahashi, et al. [2] Retrovirus Adult human fibroblasts 30 days Could differentiate into cell types of the three germ layers in vitro
Hockemeyer, et al. [14] Lentivirus + doxycycline Primary and secondaryhuman fibroblasts 20–25 days Primary and secondary human iPSCs
Huangfu, et al. [15] Retrovirus +Valproic acid VPA Human fibroblasts 30 days Resemble human ESCs in pluripotency and global geneexpression profiles
Shi, et al. [16] Retrovirus+BIX-01294,BayK8644 MEF 14–21 days Phenotypically and functionally similar to the classic mESCs
Lyssiotis, et al. [17] Retrovirus+ kenpaullone MEF 20 days Generate germline-competent chimeras
Hou, et al. [12] CHIR, 616452, FSK andDZNep (C6FZ) MEF and adult fibroblasts 40 days Differentiate into tissues of all three germ layers
iNPC Studies
Kim, et al. [12] doxycycline Doxycycline-induciblesecondary MEF 7 days
Lose capacity to self-renew after 3–5 passages in vitro and can not
differentiate into oligodendrocytes
Their, et al. [18] Retrovirus and lentivirus MEF 18 days Differentiate into neurons, astrocytes, and oligodendrocytes.
Lujan, et al. [19] doxycycline-inducible lentiviral+ tetO promoter MEF 24 days
Tripotent in vitro, but without evidence of deriving neurons and
astrocytes in vivo
Han, et al. [20] Retrovirus MEF 4–5 weeks Exhibit functionality similar to those of wild-type NPCs in vitroand in vivo
Ring, et al. [21] Retrovirus MEF and humanfetal fibroblasts 41 days Differentiate into neurons, astrocytes, and oligodendrocytes
Mitchell, et al. [22] Lentivirus adult human fibroblasts 14 days Gives rise to all three major subtypes of neural cells withfunctional capacity
Lee, et al. [23] Lentivirus + SB431542, Noggin,DN-193189, CHIR99021
Human cord blood or adult
peripheral blood cells 10–14 days
Produce astrocytes and oligodendrocytes and multiple
neuronal subtypes
Wang, et al. [24]
episomal vectors + microRNA +
CHIR99021, PD0325901, A83-01,
thiazovivin and DMH1
human urine cells 15 days differentiated into neurons and glial cells in vitro
Cheng, et al. [13] VPA, CHIR99021 and Repsox MEFs and human urinary cells Mouse 10 days;Human, 20 days
Mouse tripotent iNPCs; Human iNPC could differentiate into
neurons and astrocytes
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2. Rationale of Reprogramming to Induced Pluripotent Stem Cells (iPSCs)
2.1. The Nature of Cellular Reprogramming
To date, reprogrammed cells can be generated through the following four approaches: (a) nuclei
transfer [25]; (b) cell-to-cell fusion [26]; (c) cell extracts reprogramming [27]; and (d) direct
reprogramming [1,2]. Among the above methods, direct reprogramming is highlighted in this review
because it provides an avenue to induce a desired cell type just by introducing a set of known TFs
to donor cells via epigenetic reprogramming without actually altering the gene sequence [28]. Thus
cellular reprogramming is essentially a process to switch a cell fate from a donor cell to a desired
cell. The idea to explore the induction of iPSCs initially stemmed from the somatic cell nuclear
transfer (SCNT) research [29–31], in which the non-split nuclei from quiescent donor somatic cells
were transferred into enucleated oocytes in metaphase II. After full reprogramming by the undefined
factors in the recipient oocyte cytoplasm, the nuclei restored a totipotent state and finally gave birth
to the sheep Dolly [29]. Although Yamanaka’s group initially completed the landmark studies of
generating iPSCs from mouse by forced expression of the four TFs: Oct4, Sox2, Klf4, and c-Myc
(“OSKM”) [1,2], the human fibroblasts could not be converted into iPSCs by transduction of retroviral
OSKM under the culture condition for mouse ESCs [2]. This indicated that without an appropriate
extrinsic environment, the human iPSCs would not be produced. Altogether, these data indicated that
the induction of reprogrammed cells can only be completed by orchestrated interactions between the
intrinsic factors such as expression endogenous genes, and the extrinsic factors including the stimuli
from both cytoplasm and extracellular microenvironment.
2.2. Intrinsic and Extrinsic Factors during iPSC Reprogramming
IPSCs can only be induced under an optimized conditions defined by a combination of both,
intrinsic and extrinsic factors. In the research of generating iPSCs using a doxycycline-inducible
lentiviral system with OSKM, the “secondary” iPSCs were generated using only doxycycline treatment
from many “secondary” cells from cell line known as NGFP2 line, but not from NNeo line which
has very low levels of Sox2 and Klf4. This indicated that under suboptimal levels of intrinsic
factors (low levels of Sox2 and Klf4), the “secondary” iPSCs will not be induced by an opportune
extrinsic factor (doxycycline treatment); and after additional transduction with Sox2 and Klf4, faithful
“secondary” iPSCs were also produced from NNeo lines [32]. Additionally, the cell plating density had
a profound effect on iPSC formation, both low and high plating densities could entirely inhibit iPSC
colony formation, suggesting that in the case of improper extrinsic factor (cell plating densities), the
“secondary” iPSCs will also not be generated by proper intrinsic factors (endogenous pluripotency
genes) [32]. Particularly, there was another interesting phenomenon observed in iPSCs induction.
The “primary” reprogramming efficiency of human iPSCs from fibroblasts was significantly less than
that of mouse cells (~0.002% vs. ~0.06%, respectively); however, the reprogramming efficiency between
“secondary” human and mouse iPSCs was in the same range (~2% vs. ~4%, respectively) [32,33].
These data indicated that the interactions of similar intrinsic factors (endogenous pluripotency genes in
“secondary” fibroblasts) and the similar external environment (in cell culture condition) can produce a
similar reprogramming efficiency between different species. As a result, the appropriate levels of both
intrinsic and extrinsic factors are equally important in the process of cell fate reprogramming, both
are indispensable.
2.3. Stoichiometric Expression of Endogenous Pluripotency Genes in iPSC Reprogramming
It is now apparent that only when all endogenous pluripotency genes are expressed at optimal
levels, then iPSCs can be generated. Cowan et al. [34] demonstrated that keratinocyte-derived
primary iPSC colonies first appeared at the 18th days, and afterward the reprogramming efficiency
appeared to decline with the length of doxycycline exposure. In addition, the “secondary” fibroblasts
with high transgenic expression of Sox2 showed only moderate reprogramming efficiency due to
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increased cell death, and those with very low levels of Sox2 and Klf4 could not be expanded to
“secondary” iPSCs [32,33]. Yamaguchi et al. (2011) [35] also revealed that Sox2 played a vital
role in a dose-dependent manner in producing iPSCs, lower Sox2 expression resulting in higher
efficiency in general. Papapetrou et al. (2009) [36] further demonstrated that high Oct4 expression and
low Sox2 expression led to the highest efficiency; Oct4 activated the mesodermal gene expression
and suppressed ectodermal gene expression, and on the contrary, Sox2 facilitated ectodermal gene
expression and lowered mesodermal gene transcription [35,36]. Predominantly, the high Oct4 and low
Sox2 stoichiometry is probably required throughout the entire process of reprogramming; when all
the endogenous genes are expressed, the endogenous Oct4 levels are still high, whereas Sox2 levels
remain low [37,38], which was proved to be a “see saw model” of balance to facilitate cells reaching
full pluripotent states [39]. Any imbalance of the linage specific factors produced an undesirable fate
and failure to become iPSCs.
Collectively, the rationale for generating iPSCs can be summarized as such that, it is in nature a
process to restore the pluripotency to a somatic cell, which begins with the forced expression of suitable
exogenous transgenes/the activity of bioactive chemicals or drugs in opportune extrinsic environment,
and more importantly initiates the further reactivation of endogenous pluripotency program and an
optimal stoichiometric expression of all the endogenous pluripotency genes, which finally leads to
generation of iPSC (Figure 1).
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Figure 1. Reprogramming is the process of switching a cell fate from a donor cell to a desired cell,
needing orchestrated interactions between the intrinsic factors of endogenous genes and the extrinsic
factors from culture microenvironment such as optimal cell plating density, glass coverslip, appropriate
small molecules, and hypoxic conditions, e.g., 5% O2. The donor cells are induced to cell cycle
arrest at G p 0 (G0) phase by transient serum starvation, and synchr nized state to reenter cell cycle
after re-feeding with serum. At Gap 1 (G1) phase, the d no cells are transduced with integrative
or nonintegrative viral carriers, and returned to a transient Synthesis (S) phase. During S phase
the exogenous transcription factors (TFs) from microarray data are transcribed and synthesized
(black arrows), initiating endogenous pluripotency/multipotency gene expression (blue arrows).
The integrative viral expression is within nucleus, and nonintegrative viral expression is in the cytoplasm.
During Gap 2 (G2) phase, nucleosomes mature and histone biogenesis is repressed; the endogenous
genes are further expressed to appropriate levels (blue arrows), simultaneously, the extrinsic viral TFs
begin to be inhibited (red arrows). During Mitosis (M) phase, many TFs and chromatin binding proteins
are ejected from the chromatin; the integrative viruses are gradually silenced, and the nonintegerative
viral TFs are gradually removed from host cells (purple arrow). Finally, the desired cells such as induced
pluripotent stem cells (iPSCs) and induced neural progenitor cells (iNPCs) are induced [13,26,33,40].
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3. Methodology of Reprogramming to iPSCs
After the fundamental studies of Yamanaka and coworkers, numerous strategies have been
reported to improve the efficiency and safety of iPSC generation. The strategies are mainly explored
from the following aspects of iPSC induction: (1) screening of candidate TFs; (2) transduction of
donor cells with TFs; (3) activation of endogenous pluripotency genes; (4) regulation of cell cycle
status; (5) optimization of cell culture environment; and (6) screening of small molecules, also termed
chemical-based reprogramming, which will be discussed in the last section for both iPSCs and iNPCs
reprogramming (Figure 1).
3.1. Screening of Candidate Transcription Factors (TFs)
Screening for candidate reprogramming factors (TFs) is a key step in direct reprogramming.
The logic to select candidate TFs were on the basis of the Yamanaka’s hypothesis that the factors
responsible for maintenance of pluripotency in ESCs are also important in inducing pluripotency
in somatic cells [1]. The identification of TFs in documented papers generally followed a stepwise
process, which fell into two modes: (1) A stochastic mode, in which the candidate TFs were pick
from published papers, or by identifying the function of ESC-specific genes. Initially, Yamanaka and
coworkers stochastically selected 24 genes as candidate factors from documents to induce pluripotency.
Following a comprehensive process of systematic elimination, the combination of bona fide OSKM
factors was finally identified sufficient to induce mouse iPSCs [1], and then human iPSCs [2]; (2) In
the deterministic mode, TFs were selected from transcriptome database based on DNA microarray
data. In 2013, induced mouse oligodendrocyte progenitor cells (iOPCs) were reported by two papers
using combinations of reprogramming factors Sox10, Olig2, plus Nkx6.2 or Zfp536 [41,42]. Both of
the two studies used microarray data to deterministically identify TFs candidates, which were greatly
expressed in OPCs and oligodendrocytes comparable to other neural lineages with knowing roles
during oligodendroglia development. Dissecting the functions of the candidate transcription factors
is critical in selection process. For iPSC generation, it was known that Oct3/4 and Sox2 act as core
transcription factors of pluripotency networks by modulating the expression of pluripotency-associated
genes; Myc was known as proto-oncogene which encouraged cellular proliferation and survival; Klf4,
similarly to Homeobox Transcription Factor Nanog NANOG, could provoke leukemia inhibitory
factor LIF-independent self-renewal [3]. In the process of reprogramming to iPSCs, Oct4 and Sox2 are
initially linked with distal elements of silent genes [43] that are mainly targeted by c-Myc and Klf4 at
their promoters either by opening chromatin de novo or by maintaining the active mark [43,44], which
consequently lead to a general expression of genes [43–47]. Single-cells conversion further showed
that Oct4 is mainly responsible for cell proliferation, and Sox2 is indicative of cell pluripotency [37].
Some reprogramming genes can be functionally substituted with divergent factors. Soon after the
discovery of OSKM, another combination of factors Oct4, Sox2, Nanog, and Lin28 was also found to
be able to reprogram somatic cells to pluripotency [48]. Subsequent studies also successively showed
that OSKM can be respectively replaced with Nr5a2, Sox1, Esrrb and Glis-1 [49–54].
The core reprogramming factors remain highly conserved between different species. The typical
example is that OSKM can be used to generate iPSCs form both mouse and human fibroblasts [1,2];
and the single factor Sox2 can directly induce mouse and human iNPCs from respective fibroblasts [21].
These data indicated that the fundamental transcriptional network administrating pluri- and
multi-potency is extremely preserved in human and mouse. The comparative studies of gene
expression networks further revealed that the conservation of gene expression among human and
mouse are mainly in the transcriptional and pathway alteration responses and its constituting
substructures still have some divergences [55,56]. Consequently, in the future, direct lineage
reprogramming of human, may utilize the same core TFs that of mouse of murine, but the modifying
factors and culture conditions may be different.
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3.2. Transfection of Transcription Factors
A variety of methods have been documented to deliver TFs to donor cells for iPSCs
generation, most of which relied on biological-, chemical- or physical-based delivery system for
transfection (Figure 2). Biological-based delivery uses viral-based carriers including integrative
(retrovirus and lentivirus) and nonintegrative viral vectors (adenovirus, Epstein–Barr (EB) and Sendai
virus). Chemical-based delivery mainly includes nanocarriers, which contain DNA-, RNA- and
protein-based carriers. They are usually regarded as alternatives for viral transduction owing to
their delivery of larger transgene, low immunogenicity, easy transfection as well as low risk of gene
integration and insertional mutagenesis [57,58]. However, their efficiency and stability remain to be
improved. Physical-based delivery involves electroporation, and is seldom reported as successful
in reprogramming.
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3.2.1. Biological-Based Delivery System
Retrovirus and lentivirus both belong to integrating vectors, however, the latter can infect a
broader spectrum of host cells, including actively proliferating cells, terminally differentiated cells
and primary cells such as the myocyte or the neuron [28,59–61]. Retrovirus was firstly used for iPSCs
conversion via introducing OSKM into mouse and human fibroblasts [1,2]. The doxycycline inducible
lentiviral gene expression system was used to generate “primary” and “secondary” iPSCs from diverse
murine and human somatic cells [32–34]. Integrating viruses however, have drawbacks of insertional
mutagenesis, reactivation of transge es and uncontrolled silencing, which prompted n nintegrating
viruses to be a safer m thod for iPSCs generation.
Adenovirus, o e kind of nonintegrating carriers, has been regarded as safer m thod for in
induction of mouse and human iPSCs [62,63]. However, it caused rapid multiple organ failure and
death of a patient by its high immunogenicity at a clinical trial in 1999 [64]. Sendai virus replicates
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and transcribes in the cytoplasm of infected cells, and certainly does not integrate into the host
genome. Adenovirus has been used to produce iPSCs from human fibroblasts and cord blood cells
free of transgene footprints [40,65]. By comparison with other viral carrier, Sendai viral vectors
might meet the complex requirements for direct reprogramming, but its enzymes are sometimes not
sensitive enough to initiate/complete the reprogramming process [66]. Epstein–Barr virus is far less
immunogenic, and has effectively induced human iPSCs free of genomic integration [67], indicating EB
viruses may be well-suited for clinical translation. Nevertheless, the clinical applications are obstructed
by using viral vectors due to the risk of mutagenesis and immunogenicity, and field has shifted towards
the chemical and physical non-integrating strategies.
3.2.2. Chemical-Based Delivery System
DNA-based delivery mainly includes plasmid DNA and minicircle DNA vectors. Plasmid DNA
encoding TFs can also be employed for direct conversion of somatic cells. Among them, transposon
is a circular plasmid DNA molecule, known as a jumping gene, translocating from one DNA site to
another site [68]. Nanoparticles such as Fugene 6, has also been used in generating mouse iPSCs [1].
Minicircle DNA vectors were applied to establish footprint-free iPSC lines [69], but with 10-fold less
efficiency than viral-based methods [70].
RNA-based delivery is mostly comprised of synthetic mRNA and micro RNA. Nanoparticles
such as Lipofectamine® RNAiMAX, are frequently used to transfect mRNA [28], although at a
lower [71] reprogramming rate than that of Sendai, EB and lentiviral reprogramming. However,
when using Micro RNA (miRNA) and mRNA transfection, the success rate improved significantly to
73%, similar to other approaches. Additionally, introduction of miR-302s and miR-369s could induce
cell reprogramming [72]. Compared to DNA-based delivery, RNA-based carriers can be translated
almost instantly in cytoplasm and regarded as a non-gene therapy for not altering the host genome [73].
Nevertheless, they are short half-life, transient expression, and with apparent immunogenicity.
Protein-based delivery, termed as protein transduction domain (PTD), refers to cell penetrating
peptides (CPPs), including poly arginine and the human immunodeficiency virus transactivator of
transcription (HIV-TAT). Poly arginine consisting of 11 consecutive arginines (abbreviated as 11R)
with OSKM were used to induce mouse iPSCs [74]. In 2012, HIV-TAT PTDs were first time utilized
to reprogram human iPSCs compared to 11RPTD, indicating TAT-TFs were transcriptionally more
active than the corresponding 11R-TFs, but less than retroviral-TFs. Moreover, after linking with
cationic liposomes, HIV-TAT transduction was capable of significantly increasing the efficiency by a
1000-fold [75]. These signatures of recombinant TFs may facilitate the clinical application and genetic
material-free human iPSCs.
3.2.3. Physical-Based Delivery System
Electroporation: In this technique, an electrical field is employed to increase the permeability
of the cell membrane to allow chemicals, drugs, or DNA across the cell membrane via nano-size
pores [76]. In 2013, Green and colleagues reported that electroporation method produced faithful
iPSCs faster than poly (β-amino ester) [77]. Two years later, another group further revealed that
Mesenchymal-to-Epithelial Transition occurring at approximately 6–12 days after electroporation
in the process of reprogramming to iPSCs [78]. Electroporation has many advantages such as its
technical simplicity, the ability to transiently or stably transfect whole populations of cells and its broad
application for transfer of any macromolecule. Unfortunately, there are only few papers successfully
using electroporation in cell fate reprogramming to date.
3.3. Activation of Endogenous Pluripotency Genes
Activating the expression of endogenous pluripotency genes is a key step in generation of iPSCs.
Hotta et al. (2008) [79] demonstrated that pluripotent cells, different from somatic cells, have a capability
to silence retroviruses by de novo DNA methylation and other mechanisms. Partly reprogrammed cells
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show partial silencing and continued expression of the retroviral OSKM genes, and fully reprogrammed
cells show entire reactivation of endogenous pluripotency genes and silencing of all the viral factors.
Additionally, the iPSCs induced by diverse nonintegrating deliveries such as Sendai and EB viral
vectors or some nanocarriers, also showed reactivation of OSKM genes, and the carriers were all
gradually eliminated during the process of reprogramming [40,67,71]. In particular, some iPSCs
could be induced using only combination of small molecules without exogenous transgenes [17]
indicating that the ability of small molecules to activate the endogenous pluripotency genes is
different from viruses and nonviral carriers. Overall, faithful reprogramming is not dependent
on continuous activation and expression of the exogenous transgenes, but on reestablishment of the
autoregulatory loop involving the reactivation and expression of all endogenous pluripotency genes
to an opportune level.
3.4. Regulation of Cell Cycle Status for Reprogramming
Since the first reports of iPSCs generation [1], a variety of techniques have been used to develop
more efficient methods for reprogramming. However, the conversion efficiency is still very low
(0.001%–0.1%) [1,2,49,58]. The basis for the low efficiency is weakly understood, but some studies
implied the stochastic transfection and genetic heterogeneity of donor cells partially contributed to the
results that only a very small fraction of infected cells ultimately converted to pluripotency [1,2,49].
To solve this problem, some studies have exhibited that alleviation of the cell cycle arrest, by promoting
S-phase entry, could improve the reprogramming efficiency of iPSCs by achieving synchronization in
donor cells [80–82] (Figure 1).
The detailed mechanism regarding the influence of cell division on reprogramming remains
unclear. However, several papers demonstrated the importance of donor cell cycle in
reprogramming [83,84], since it is observed that self-renewal and stemness of iPSCs is reassumed
during the process of donor cell division. The iPSCs, similar to ESCs, show an atypical cell cycle
structure characterized by a short Gap 1 (G1)-phase and prolonged Synthesis (S) phase, which is
intimately linked to the self-renewal and pluripotency and beneficial to the synthesis and expression
of pluripotency genes in ESCs compared to differentiated somatic cells [85–87]. Little is known about
the link between acquisition of stem cell properties and altered cell-cycle structure. A truncated
G1-phase might protect ESCs from external induction of differentiation, and prolonged S-phase may
be beneficial to synthesize and express the pluripotency of ESCs compared to the differentiate somatic
cells [80,81,88]. The active promotion of the transition through S-phase might tolerate epigenetic
resetting of the genome and/or encourage proliferation to increase the number of cells accessible
for stochastic reprogramming. Facilitation though G1 to S-phase of cell cycle requires the stepwise
phosphorylation and inactivation of retinoblastoma [89]. This phosphorylation is adjusted by cyclin
dependent kinase (CDK), which needs the binding of cyclins (Cyc) for their functional activation [90].
Belmonte et al. (2011) [83] observed a 10-fold increase in the reprogramming efficiency by co-expressing
CycD1/CDK4 in BJ fibroblasts, whereas downregulation of CycD2 led to a permanent cell cycle arrest
in the donor cells undergoing reprogramming, suggesting that S phase offers an unrivaled opportunity
to reset or reprogram gene expression profiles [84]. Chen et al. (2012) [82] utilized transient serum
starvation (18 h) to induce a reversible cell cycle arrest at Gap 0 (G0) phase. After re-feeding with
serum, they harvested a clear enrichment of S-phase in synchronized human dermal fibroblasts (20 h),
and finally achieved 1.4% Nanog positive clones, which were 15–20 folds higher than unsynchronized
conversion. Taken together, the cell-cycle stage of the donor cells is probably vital for successful
reprogramming, and S phase provides a window of opportunity to remodel the pluripotent gene
expression profiles.
Regardless of the strategy of cell cycle regulation employed in cellular reprogramming, the
underlying machinery at this time is unknown. However, by studying the basic molecular activities
of each phase during cell cycle, some cues feasible for the epigenetic remodeling may be found [91].
The cell cycle consists of Gap 1 (G1), Synthesis (S), Gap 2 (G2), and Mitosis (M) phase. Gap 0 (G0) refers
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to the time when a cell leaves the cycle and quit dividing, which may be a temporary resting period or
more permanent. Serum starvation is frequently applied to induce a reversible cell cycle arrest at G0
phase [29,82]. G1, Cells produce RNA and synthesize protein in this time, ensuring everything is ready
and activated for DNA synthesis. In S phase, the complete DNA instructions must be duplicated so as
to produce two similar daughter cells. This stage is an essential part of cell cycle because many proteins
that are involved in epigenetic inheritance such as DNA methyltransferase 1 and chromatin assembly
factor-1 CAF-1, and in DNA synthesis such as DNA polymerases, replication protein A and processivity
clamp proliferating cell nuclear antigen (RPA, and PCNA respectively), are known to colocalize at
“replication foci” during this phase. Additionally, some enzymes, modifying histones, constantly
connect with their response elements also in this period [92–95]. G2 phase serves as checkpoints
to make sure everything ready to enter Mitosis (M) phase. If necessary, the cell will make proper
amendment of DNA synthesis and other intracellular components. M phase, chromosomes condense,
and many transcription factors and chromatin binding proteins are ejected from the chromatin. All of
the cell's energy is focused on the complex and orderly division into two similar daughter cells [92].
This implies that transducing at G1 phase leading to transition through S phase may offer opportunity
potential window for direct reprogramming to occur.
3.5. Optimization of Microenvironment for Reprogramming
Cell fate reprogramming relies not only on the roles of reprogramming genes but also on the
influences of external microenvironment (culture conditions). For example variations in oxygen
tension, cell-cell contact, paracrine signaling, and extracellular matrix, has received considerable
attention in the epigenetic landscape and transcriptome of iPSCs conversion. Yoshida et al. (2009) [96]
achieved enhanced efficiency in iPSCs reprogramming under the hypoxic condition of 5% O2 through
retroviral or even non-viral transduction. Their results were confirmed by Liu et al. [97] who produced
a novel iPSCs under 3% O2, which showed efficacy after transplanting them to ischemic stroke model
in mouse. Extracellular matrix also seems to play an important role in reprogramming. For example,
in reprogramming of iNPCs from mouse and human fibroblasts with Sox2, the morphology of mouse
embryonic fibroblasts (MEFs) plated on gelatin coated glass coverslips were drastically changed
2–10 days after sox2-viral transduction, but remained unchanged and failed to reprogram for up to
four weeks on gelatin coated plastic dishes [21]. Moreover, the efficiency of generating Nestin+/Sox2+
colonies from MEFs was greater on poly-L-ornithine/laminin-coated glass coverslips than on gelatin
on Day 8 after transduction [21]. Similarly, the cell plating density also has a critical effect on iPSC
formation. The plating density at 2.5~25 cells/mm2 showed the highest efficiency in induction
of “secondary” iPSCs, both lower and higher plating densities could almost inhibit GFP+ colony
development, indicating that paracrine factors might be initially required to facilitate iPSC growth,
and fundamental cell proliferation will be impeded if cells are contact-inhibited before activation of
the transgenes [32]. Altogether, the above-mentioned data suggest that besides reprogramming genes,
the culture microenvironment is another determinant in the process of lineage reprogramming.
4. Rationale of Reprogramming to iNPCs
The transdifferentiation of iNPCs from fibroblasts is achieved through two different
reprogramming techniques. Namely, the “indirect reprogramming” refers to use of the OSKM factors
to induce iNPCs from fibroblasts, passing through an intermediate transient state by addition of
specific growth factors to the reprogramming medium. “Direct reprogramming” on the other hand,
means direct generation of iNPCs from fibroblasts by using lineage-specific transcription factors,
bypassing the transient pluripotent stage. Here, we will discuss the rationale of both indirect and
direct reprogramming to iNPCs.
“Indirect reprogramming” was first reported by Kim et al. (2011) [12]. They initially aimed
to establish a more general conversion strategy to produce a broad array of unrelated desired cell
types including lineage-committed precursors earlier studies demonstrated that numerous partially or
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incompletely reprogrammed cells, expressing multiple lineage-specific markers, did not show specific
physiological function in the process of iPSC transdifferentiation [1,98], indicating that pluripotency
may be only one of many possible outcomes of the four-factor reprogramming, and the eventual
result may largely rely on extrinsic signaling conditions. Accordingly, they hypothesized that it may
be possible to deliberately switch the early reprogramming process toward a defined cell type by
using specific permissive signaling inputs, after which the desired cells could be obtained. Based
on this hypothesis, they successfully converted fibroblasts not only into functional iNPCs, but also
into spontaneously contracting cardiac cells by temporary expressing the same OSKM factors under
different culture conditions. The results suggested that changing the duration of transgene expression
and the culture conditions to a transient, plastic developmental state could effectively serve as a cellular
platform for reprogramming toward diverse lineages. The study forms a basis of a methodology for
interlineage reprogramming into multi- or oligo-potent cells.
Regarding “direct reprogramming” to iNPCs, the rationale is similar to that of transdifferentiation
to iPSCs, as depending on the expression of all endogenous multipotent NPC genes, which were
reactivated by extrinsic transgenes or chemicals under NPC favorable condition. However, the extrinsic
transcription factors appeared to be more flexible than those of iPSCs. The iNPCs could be directly
transdifferentiated from somatic cells via either Sox2-based/Sox2 alone, or Oct4-based/Oct4 alone
methods, whereas the iPSCs could only be induced by OSKM factors or other functional substitutes.
5. Methodology of Reprogramming to iNPCs
Several strategies have been explored in the production of iNPCs, among which viral-based or
chemical-based approaches have been used successfully (Figure 3). Although the physical-based
method involving electroporation has been reported in a few studies to induce integration-free NPCs
from human urine cells and porcine fetal fibroblasts [24,99], the nanocarrier-based methods have not
yet been extensively explored in iNPC transdifferentiation. A number of studies have demonstrated
that the virally-induced reprogramming of iNPCs can be achieved by three principal approaches:
expression of four pluripotent factors (OSKM), expression of neural specific factors, or expression
of Oct4.
In the indirect conversion to iNPCs by Kim et al. (2011) [12], they induced iNPC from
doxycycline-induced “secondary” MEFs by reactivation of the typical four iPSC factors (OSKM)
with doxycycline under neural reprogramming conditions. However, their iNPC had a few limitations;
namely, they quickly lose their capacity to self-renew and to form colonies after 3–5 passages in vitro.
Moreover they were not tripotent, and could not differentiate into oligodendrocytes. Meyer et al.
(2005) [100] directly converted adult human fibroblasts into iNPCs by timely restricted expression of
all OSKM factors. After 17 days, Sox2-positive neuroepithelial colonies were established, which could
only be differentiated into neurons and astrocytes as well. In order to directly achieve faithful iNPCs,
Thier et al. (2012) [18] used same cocktail of four iPSC factors, while limiting the Oct4 expression
after the first five days during the process of transdifferentiation due to the knowledge that NPCs
endogenously express only three of the four iPSC transcription factors (c-Myc, Klf4, and Sox2, but
not Oct4). Eighteen days after transduction, they harvested neurosphere-like colonies for further
characterization, which revealed great similarity between iNPCs and wt NPCs derived from mouse
brain, indicating the crucial role of the three factors Sox2, Klf4, and c-Myc in iNPCs transdifferentiation.
In a different study, Lujan et al. (2012) [19] obtained tripotent iNPCs from mouse fibroblasts
capable of differentiating into neurons, astrocytes and oligodendrocytes using a different four-factor
cocktail of lentiviral Sox2, FoxG1, Pou and Brn2. This work evidently confirmed the possibility
of achieving self-renewing, multipotent iNPCs using neural-specific reprogramming factors rather
than iPSC-related factors. However, this method still carries a reduced risk of tumourigenesis after
transplant to animal owing to the constant undifferentiated cells or transgene reactivation; meanwhile
it did not show any evidence of deriving neurons and astrocytes from the iNPCs in vivo. However, in
another study, Han et al. (2012) [20] induced a pure population of iNPCs using retroviral Sox2, Klf4,
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c-Myc, and Brn4 from MEFs, which showed the same epigenetic modifications and multipotentiality
of wild typeNPCs. Moreover, the efficiency became higher after infection with a five-factor cocktail47).
The iNPCs could be subcultured for more than 130 times, and evidenced capacity of committing both
to the neuronal and to the glial lineages, without forming teratomas after transplantation. This study
demonstrated once more the critical role of Sox2, Klf4, c-Myc in induction of iNPCs. However, this
study focused on mouse iNPCs reprogramming, and the rate of oligodendrocyte differentiation from
iNPCs requiring to be enhanced. Thereafter, new method needs to be explored to further improve the
multipotency of iNPCs and to induce iNPCs from human somatic cells.
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Figure 3. (A) A schematic diagram showing iNPC reprogramming from mouse embryonic fibroblasts
(MEFs) using four pluripotent factors (OSKM) under neural reprogramming conditions. Neural
induction medium with growth factors can deliberately switch the early iPSC reprogramming process
toward NPC fate. During the process, the intermediate cells express Pax6, nestin, and Sox2 marks [12].
After restricted Oct4 expression, tripotent iNPCs were obtained without using growth factors in
reprogramming medium, indicating the crucial role of the three factors Sox2, Klf4, a d c-Myc in
iNPCs transdifferentiation [18]; (B) the cheme of iNPC conversi n from MEF and human fetal
fibroblasts using neura pecific factors. Sox2 and nestin were expressed in inter ediate cells [19–21];
(C) a schematic showing iNPC conversion from h ma blood progenitors and fibroblasts via Oct4
factor in neural induction medium with growth factors. The intermediate cells express both Oct4 and
Sox2 marks. Tripotent iNPCs can be even induced from adult human fibroblasts using Oct4 alone,
indicating iNPC could be mediated through Oct4 trajectory different from Sox2 [22,23].
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Ring et al. (2012) [21] established a homogeneous population of iNPCs from both MEF and
human fetal fibroblasts by using only a single factor, retroviral Sox2, which differentiated into neurons,
astrocytes, and oligodendrocytes both in vitro and in vivo. The human iNPCs however, showed
morphological and self-renewal properties, which lasted for fewer passages than mouse iNPCs.
Fortunately, the human iNPCs were capable of differentiating into three main neural cell types
under opportune conditions in vitro. Su et al. (2013) [101] also direct converted MEF into neural
progenitor-like cells by forced growth into 3D spheres on low attachment surfaces and transfected
with only a lentival Sox2 factor. These studies highlighted the crucial role of Sox2 as a “master
reprogramming gene” for producing iNPCs from differentiated cells.
Mitchell et al. (2014) [22] demonstrated that they had directly generated tri-potent neural
progenitors from adult human fibroblasts using Oct-4 alone. Human Fib-NPC (Oct-4) could proliferate
and express neural progenitor markers, as well as possess the potential to gives rise to three major
neural subtypes, astrocytes, oligodendrocytes, and neurons with functional capacity. Their data
indicated Oct4 is sufficient for inducing neural conversion from human fibroblasts. Bhatia et al. [23]
enerated iNPCs from neonatal and adult peripheral blood progenitors using Oct4 + SMAD + GSK-3
inhibitors. Interestingly, expression of Sox2 alone failed to induce hiNPCs under these conditions,
suggesting the complexity of the mechanism underlying human iNPC reprogramming.
6. Chemical-Based Reprogramming to iPSCs and iNPCs
Conventional viral-based reprogramming has been proved feasible for generation of iPSCs and
iNSCs, however, this method carries the risks of genomic integration, mutagenesis and oncogene
expression into host cells [10,11,28]. This has largely prevented this approach from moving towards
clinical application. Since this issue also obstructs the therapeutic use of reprogrammed cells such as
iPSCs and iNPCs, chemical/small molecule-based reprogramming, as an alternative strategy, has been
explored (Figure 4).
In molecular biology and pharmacology, small molecules refer to the organic bioactive compounds
with a low molecular weight less than 900 daltons and a size about 10´9 m. Most medicines are small
molecules. Compared to routine genetic methods, small molecules present several distinct merits:
(1) they can rapidly regulate cell functions and even functionally replace some exogenous TFs with
higher precision in a temporal and reversible manner; (2) they can be used at adjustable concentrations
and combinations with tunable effects; and (3) they are nonimmunogenic, cell permeable, more
cost-effective to synthesize, and easier to preserve. Simultaneously, most of chemical-mediated actions
are nonspecific; a specific small molecule may work on multiple targets. This feature often presents
a challenge for applying them and elucidating the effects in cell reprogramming, however, it is also
an opportunity to apply them to some direct lineage reprogramming without knowing the definite
reprogramming TFs. These signatures help to improve their efficacy and safety, and be potentially
applied in clinical practice.
Most studies demonstrate that the general logic and strategy of using small molecules in
transdifferentiation was to replace part or total of the transgenes in different cell fate reprogramming
contexts without causing permanent modification to the somatic genome [102,103]. If the epigenetics
of target endogenous genes can be regulated by chemicals to enter an active gene status, then there is
no need to express ectopic genes [104].
The main function of small molecules in reprogramming is supposedly to activate the silent
genes via modulating DNA and histone methylation as well as histone acetylation, so that they are
able to undergo reactivation and transcription [105]. According to their functions during cell fate
reprogramming, small molecules can be mainly assigned into the following four classes: (a) epigenetic
enzyme inhibitors; (b) nuclear receptors agonists; (c) metabolic modulators; and (d) signaling pathway
regulators. For more detailed reviews, please refer to Yu et al. [103] and Biswas and Jiang [104].
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Figure 4. Chemical-based reprogramming to chemically induced pluripotent stem cells (ciPSCs) and
chemically induced neural stem cells (ciNSCs): (A) Schematics of direct iPSC transdifferentiation
from mouse embryonic fibroblasts (MEF) using seven small-molecule cocktail leading to GFP-Oct4
expressing ciPSCs generation. After in vivo transplantation, the ciPSCs can differentiate into cells of
all three germ layers. After screening, the four small molecules, C6FZ (CHIR99021, 616542, Forskolin
and DZNep) were found to be critical in inducing CiPSCs [17]; (B) direct ciNSC reprogramming from
MEFs and human urinary cells using a three small-molecule cocktail VPA, CHIR99021, and Repsox
(VCR) under hypoxic condition (5% O2) [13].
6.1. Chemical-Based Reprogramming of Somatic Cells to iPSCs
A vital epigenetic mechanism that controls gene expression is DNA methylation of the
promoter. Gene promoter methylation can stably inactivate gene expression by blocking binding of
cell-fate-determining TFs to the respective promoter to initiate transcription. Valproic acid (VPA),
reported by Huangfu et al. [14], was the first small molecule applied to facilitate reprogramming of
ciPSC, in which it could replace of the oncogenes c-Myc and Klf4 and enhance the iPSC reprogramming
efficiency 100-fold over that of the OSKM method. VPA, trichostatin A (TSA), and butyrate are all
histone deacetylases (HDAC) inhibitors; they can improve reprogramming and replace c-Myc via
regulating lysine acetylation of histones and loosing chromatin to express transcription [106,107].
Ding et al. (2008) [15], revealed that a specific inhibitor for G9a histone methyltransferase (HMT)
inhibitor BIX-01294, and BayK (a L-type calcium channel agonist) can enable MEF converting into iPSCs
in the presence of Oct4 and Klf4. BIX may functionally facilitate the epigenetic switching of endogenous
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pluripotency genes from a silenced state to an active transcription state for cell fate reprogramming.
Ten-eleven translocation (Tet) enzymes, convert 5-methylcytosine to 5-hydroxymethylcytosine in
DNA, as the initial step in activating DNA demethylation [108,109], which not only facilitate Oct4
demethylation and reactivation, but also functionally substitute exogenous Oct4 [110]. Vitamin C
was shown to enhance the generation of iPSCs, at least partly owing to its Tet-dependent induction
of DNA demethylation [111]. Tranylcypromine, as H3K4 demethylation inhibitors, were shown to
promote iPSC generation in the absence of c-Myc [112]. DZNep, as an S-adenosylhomocysteine (SAH)
hydrolase inhibitor, can reduce the total levels of histone methylation related with heterochromatin
including H3K9, H3K27, and H4K20 methylation [113,114].
Nuclear receptors (NR) are ligand-regulated transcription factors. The major function of NRs is to
directly bind DNA and adjust gene expression. As an orphan nuclear receptor, Nr5a2 and its close
family member Nr5a1 are capable of both enhancing reprogramming and replacing Oct4 [50]; Esrrb,
along with Oct4 and Sox2, can directly activate pluripotency gene Nanog [53]. Together with Nr5a2,
RARa/g greatly enhanced reprogramming kinetics and efficiency [50].
Among metabolic modulators, forskolin (FSK), a cAMP agonist, can act as a chemical substitute
for Oct4 [17]. Compared with somatic cells, many stem cells depend more heavily on aerobic glycolysis.
Many small molecules promote reprogramming via encouraging glycolytic metabolism and acting
directly on metabolic pathways, such as fructose 2,6-bisphosphate and Quercetin. On the contrary, a
glycolysis inhibitor, 2-deoxy-D-glucose, can inhibit conversion [115].
A majority of small molecules are signaling pathway regulators and thereby modulate cell
transdifferentiation. Some signaling pathways even directly link to the pluripotency transcriptional
network to positively regulate pluripotent state. Kenpaullone, like CHIR99021, both inhibit GSK-3β
and enhance OSKM-based reprogramming, and Kenpaullone can also replace Klf4 [16], which is
consistent with the mechanism under WNT stimulation. However since these chemicals show no
cell-type specificity, they may be helpful to induce pluripotency by a general open chromatin state, but
they won't be capable of directly converting a cell to another differentiated cell type.
Deng and colleagues (2013) were the first group to demonstrated generation of mouse iPSCs by a
complete chemical combination of seven small-molecules, with an efficiency of 0.2% (higher than that
of Yamanaka’s protocol, 0.01%–0.1%) [17]. After systematic identification, they demonstrated that four
chemicals (C6FZ) including CHIR, 616452 (a transforming growth factor-β inhibitor); FSK and DZNep
(Z) were indispensable. This study presented the proof of principle that in the context of using small
molecules, exogenous “master genes” are dispensable during cell reprogramming, indicating that
pure-chemical reprogramming strategy has great potentiality in generating functional reprogrammed
cells for clinical cell therapy. If human ciPSC line can be established by complete small molecule
method in the near future, it will be tremendously exciting.
6.2. Chemical-Based Reprogramming to iNPCs
Wang et al. (2013) [24] transfected epithelial-like cells from human urine with episomal vectors
carrying Oct4, Sox2, SV40LT, Klf4 and microRNA cluster MIR302–367 through electroporation,
and cultured the transfected cells in presence of five chemicals: CHIR99021, PD0325901, A83-01,
thiazovivin and DMH1. Fifteen days later, NSC colonies were picked up and differentiated into
neurons and glial cells in vitro. Ding et al. (2014) [116] reported that ectopic expression of Oct4
combined with a chemical combination of A83-01, CHIR99021, NaB, LPA, rolipram, and SP600125,
could convert AHDF into hiNPC colonies, that homogeneously expressed the neural stem cell marker
PAX6, whereas ectopic expression of Sox2 alone under the same conditions failed to produce hiNPC
colonies. Similarly, Bhatia et al. [23] demonstrated that iNPCs could be obtained from human blood
cells using single-factor Oct4, which could be facilitated by SMAD + GSK-3 inhibitors (SB431542,
LDN-193189, Noggin, CHIR99021). Blood-derived iNPCs could differentiate into astrocytes and
oligodendrocytes and multiple neuronal subtypes, including dopaminergic (central nervous system
related) and nociceptive neurons (peripheral nervous system) in vitro. No detectable iNPC-like clusters
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appeared upon expression of Sox2 alone, and efficiency of iNPC formation was significantly reduced
when employed together with Oct4, indicating Sox2-mediated hiNPC transdifferentiation may follow
a different trajectory from Oct4-mediated hiNPC transformation.
Pei and colleagues (2014) for the first time demonstrated the generation of chemically induced
ciNPCs from both MEFs and human urinary cells by a cocktail of three chemicals: VPA, CHIR99021
and Repsox, (VCR), under a hypoxic condition (5% O2) without introducing any exogenous genes [13].
Moreover, the other inhibitors of the same pathways could also induce ciNPCs with similar efficacies.
This chemical reprogramming was accompanied by activating the expression of endogenous Sox2.
These mouse ciNPCs resembled brain-derived NPCs in both cell identities and multipotency for all
three neural cell types in vitro and in vivo; nevertheless, the human hUC-derived ciNPCs could only
differentiate into neurons and astrocytes, not oligodendrocytes. Han et al. (2016) [117] also reported an
efficient approach to convert MEF into iNPC using a seven combination of small molecules (valproic
acid, Bix01294, RG108, PD0325901, CHIR9901, vitamin C, and A83-01). The iNPCs closely resemble
wild type NPC and are able to differentiate into astrocytes, functional neurons, and oligodendrocytes
in vitro and in vivo. Consequently, further development and optimization of complete chemical
reprogramming to produce tri-potent human ciNPCs will be promising for treating neurological
diseases such as multiple sclerosis, Parkinson’s disease and Alzheimer’s disease.
7. Concluding Remarks and Future Perspectives
During the past 10 years since the generation of iPSC, significant improvements have been
incorporated to increase the efficiency and safety of this technique, making it more amenable mainly
for clinical applications in the fields of regenerative medicine, but also for disease modeling and
therapeutic discovery. Moreover, the somatic cell reprogramming technology has also opened many
avenues for direct lineage reprogramming, which bypasses the iPSC stage and thereby avoids the
potential risk of teratoma development. In this context, the iNPCs have been established using viral
and nonviral transduction methods. For autologous transplantation, iNPCs could be a great alternative
therapy or an essential support to pharmacological treatment. iNPCs should be ideally obtained by
avoiding dangerous oncogenic vectors. Compared to viruses, small molecules having their distinct
advantages such as easy handling, non-immunogenicity, rapid and reversible effects, might meet the
complex requirements for cell fate transformation. However, this technology is far from maturity up
to now. Future directions for fate conversion greatly rely on a deeper understanding of mechanisms
governing cell identity, plasticity and epigenetic regulations. Despite many challenges, exploiting
chemical-based reprogramming for the purpose of generating human ciPSCs or ciNPCs through
epigenetic conversion, will make this field an attractive platform to translate the work from bench to
bedside for regenerative medicine.
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